Article Sidebar

PDF
Date Published: 12/01/2022
Abstract Views: 588
Views PDF: 295
DOI: https://doi.org/10.51298/vmj.v509i1.1761
Issue
Vol. 509 No. 1 (2021)
Section
Các bài báo
How to Cite
Thị Huyền, P. . (2022). EFFICACY OF NEOADJUVANT THERAPY WITH CHEMOTHERAPY COMBINED WITH TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HER2-NEU POSITIVE BREAST CANCER. Vietnam Medical Journal, 509(1). https://doi.org/10.51298/vmj.v509i1.1761

EFFICACY OF NEOADJUVANT THERAPY WITH CHEMOTHERAPY COMBINED WITH TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HER2-NEU POSITIVE BREAST CANCER

Phùng Thị Huyền1,
1 K Hospital

Main Article Content

Abstract

HER2-neu targeted therapy in combination with chemotherapy has been the standard treatment for HER2-neu positive cancer in the world. In Vietnam, Trastuzumab has been used since 2016 while Pertuzumab has just recently been used. This is a descriptive cohort study evaluating the efficacy of neoadjuvant Trastuzumab and Pertuzumab in combination with chemotherapy for HER2-neu positive breast cancer at K hospital from 01/2018 to 04/2021. The results on 20 patients showed that the clinical overall response rate was 95.0%, with only one patient progressed. Total pathological complete response (tpCR) rate was 80.0%. There were no associations between tpCR and age, tumor and nodal stage, histological type and grade, ER, PR, Ki67 status and chemotherapy regimen. The regimens were well tolerated and no patients had treatment delay or interruption due to toxicities.

Article Details

Keywords

neoadjuvant, Pertuzumab, HER2-neu positive breast cancer

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
2. Chumsri S, Li Z, Serie DJ, et al. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(35):3425-3435. doi:10.1200/JCO.19.00443
3. Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19 (20): 5552-5556. doi:10.1158/1078-0432.CCR-13-0518
4. Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomisedmulticentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9
5. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol Off J Eur Soc Med Oncol. 2013;24(9):2278-2284. doi:10.1093/annonc/mdt182
6. Phung HT, Nguyen HT, Nguyen TV, Nguyen TV, Dinh LAT, Nguyen CV. Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam. Breast Cancer Dove Med Press. 2020;12:117-122. doi:10.2147/BCTT.S268369
7. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(25):3351-3357. doi:10.1200/JCO.2010.31.4930
8. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(12):2024-2031. doi:10.1200/JCO.2009.23.8451
9. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | NEJM. Accessed June 11, 2021. https://www. nejm.org/doi/full/10.1056/nejmoa1703643